相似文献
1
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?
CMAJ. 2003 Jun 24;168(13):1689.
2
What are the odds at ASCOT today?
Lancet. 2003 Apr 5;361(9364):1144-5. doi: 10.1016/s0140-6736(03)12977-7.
3
No difference in plasma fibrinogen levels between CAPD patients taking atorvastatin and simvastatin.
Perit Dial Int. 1999 Jan-Feb;19(1):89-91.
4
[Atorvastatin for primary prevention of cardiovascular events. ASCOT-LLA Study].
Internist (Berl). 2004 Mar;45(3):355-7. doi: 10.1007/s00108-003-1129-8.
5
ASCOT-LLA: questions about the benefits of atorvastatin.
Lancet. 2003 Jun 7;361(9373):1986; author reply 1986-7. doi: 10.1016/S0140-6736(03)13560-X.
6
Cholesterol levels and the benefit of statins in heart failure.
Hellenic J Cardiol. 2005 May-Jun;46(3):226-31.
7
ASCOT-LLA: questions about the benefits of atorvastatin.
Lancet. 2003 Jun 7;361(9373):1985-6; author reply 1986-7. doi: 10.1016/s0140-6736(03)13558-1.
8
ASCOT-LLA: questions about the benefits of atorvastatin.
Lancet. 2003 Jun 7;361(9373):1987-8. doi: 10.1016/s0140-6736(03)13563-5.
9
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Lancet. 2003 Apr 5;361(9364):1149-58. doi: 10.1016/S0140-6736(03)12948-0.
10
[To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
MMW Fortschr Med. 2005 Aug 18;147(33-34):51.
引用本文的文献
1
No absolutes.
CMAJ. 2003 Sep 30;169(7):651; author reply 651.
本文引用的文献
1
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Curr Med Res Opin. 2002;18(4):220-8. doi: 10.1185/030079902125000787.
2
Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies.
Circulation. 2001 Dec 4;104(23):2855-64. doi: 10.1161/hc4701.099488.
3
Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.
Circulation. 2000 Jul 11;102(2):157-65. doi: 10.1161/01.cir.102.2.157.
Zotero 插件